Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Did Our Founding Fathers Get It Right?

August 28th 2013

Only Time Will Tell the Far-Reaching Societal Implications of the Supreme Court's BRCA 1/2 Ruling

TNBC Studies Yield Clues for Future Directions

August 27th 2013

Researchers are still at the drawing board when it comes to finding revolutionary solutions for the treatment of triple-negative breast cancer, but studies have shed light on the diversity of the disease and offered hints about the directions future inquiries should take.

Dr. Ho on Postmastectomy Radiation Therapy

August 22nd 2013

Alice Y. Ho, MD, discusses postmastectomy radiation therapy for patients with breast cancer who have undergone breastreconstructive surgery.

Dr. Finn on New CDK 4/6 Inhibitors for Breast Cancer

August 19th 2013

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses new CDK 4/6 inhibitors for the treatment of breast cancer.

Subgroup Analysis: Certain Patients May Benefit More From Eribulin

August 19th 2013

A subgroup analysis from a phase III study showed that certain patients may benefit more from eribulin than capecitabine, and quality of life data suggest that patients may prefer eribulin because of a lower frequency of certain adverse events.

More Genetic Screening Needed for African-American Breast Cancer Patients

August 15th 2013

One in five African-American women with breast cancer carries an abnormality in at least one gene associated with breast cancer susceptibility.

Dr. Nielsen Discusses Using a Ki67 Assay in Breast Cancer

August 13th 2013

Torsten O. Nielsen, MD, PhD, FRCPC, professor, pathology, University of British Columbia, on using a Ki67 assay for patients with breast cancer.

CTC-Based Biomarkers Can Be Measured for Sensitivity to Novel Breast Cancer Drug

August 9th 2013

Biomarkers for sensitivity to etirinotecan pegol that are found in circulating tumor cells of breast cancer patients can be "reliably measured."

Dr. Rugo on PI3K and mTOR Inhibitors for Breast Cancer

August 8th 2013

Hope S. Rugo, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, gives an overview of the development of PI3K and mTOR inhibitors for the treatment of breast cancer.

Tamoxifen Significantly Lowers Risk of Contralateral Breast Cancer in BRCA-Positive Patients

August 6th 2013

Patients with mutations of BRCA1 or BRCA2 who received tamoxifen after their initial diagnosis of breast cancer reduced their chances of developing contralateral or secondary breast cancer by more than half.

Breast Cancer Heterogeneity Confounds Trial of Dual HER2-Targeted Therapy

August 5th 2013

Exploratory analyses by intrinsic subtype showed that HER2-positive breast cancer is molecularly heterogeneous with varying degrees of sensitivity to HER2-targeted therapy.

Dr. Swain on Pregnant Patients With Breast Cancer

August 5th 2013

Sandra Swain, MD, from the Washington Cancer Institute at MedStar Washington Hospital Center and Georgetown University Medical Center, discusses pregnant patients with breast cancer.

Dr. Hershman on Adherence to Longer Hormonal Therapy

August 1st 2013

Dawn L. Hershman, MD, MS, Associate Professor of Medicine and Epidemiology, Leader, Breast Cancer Program, Herbert Irving Comprehensive Cancer Center, Columbia University, discusses the need for adherence with longer hormonal therapy.

Dr. Tripathy on Targeting HER2 in Breast Cancer

July 31st 2013

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses targeting HER2 in breast cancer.

Dr. Albain on the 21- and 70- Gene Assays in Breast Cancer

July 26th 2013

Kathy S. Albain, MD, from the Loyola University Chicago and Cardinal Bernardin Cancer Center, discusses the difference between the 21-gene (Oncotype DX) assay and 70-gene (MammaPrint) assay in breast cancer.

Dr. Aft on Identifying Markers for Micrometastatic Disease

July 24th 2013

Rebecca L. Aft, MD, PhD, from the Siteman Cancer Center, discusses the need to identify markers for patients with micrometastatic disease.

BOLERO-3: Everolimus Might Help Patients Overcome Trastuzumab Resistance

July 23rd 2013

Adding the mTOR inhibitor everolimus to conventional therapy slowed the progression of trastuzumab-resistant advanced breast cancer, and in the process, provided clues to the origin of trastuzumab resistance.

Dr. Minetta Liu on CTCs for Prognosis and Prediction

July 23rd 2013

Minetta Liu, MD, Breast Cancer Specialist, Mayo Clinic, Rochester, Minnesota, discusses the use of circulating tumor cells (CTCs) for prognosis and prediction in patients with breast cancer.

Dr. Lehman on Breast Imaging Across Cancer Centers

July 22nd 2013

Constance D. Lehman, MD, PhD, from the Seattle Cancer Care Alliance, discusses breast imaging across various cancer centers.

Adding Paclitaxel to Neratinib Improves Outcomes Versus Monotherapy

July 22nd 2013

Combining paclitaxel with the investigational compound neratinib increased response rates versus neratinib alone in patients with HER2-positive metastatic breast cancer.